+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asthma and COPD Drugs Market by Diseases and Medication Class (Combination Drugs, Inhaled Corticosteroids, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others.): Global Opportunity Analysis and Industry Forecast, 2021--2030

  • PDF Icon

    Report

  • 120 Pages
  • February 2022
  • Region: Global
  • Allied Market Research
  • ID: 5578213
Description Jump to:
The asthma and COPD drugs market was valued at $32988.7 million in 2020 and is projected to reach $52049.54 million by 2030, registering a CAGR of 4.64%% from 2021 to 2030.



Asthma is a respiratory disorder, in which there is narrowing of bronchi that leads to difficulty in breathing. Asthma patients may suffer with shortness of breath, chest tightness or pain, and wheezing sound while exhaling. Chronic Obstructive Pulmonary Diseases (COPD) is a group of respiratory disorders, which mainly includes emphysema and chronic bronchitis.

Asthma and COPD can be diagnosed by performing X-ray imaging, nitric oxide test, and sputum examination test. Asthma and COPD have broncho constricton as common symptoms and can be treated with corticosteroids, anticholinergic drugs, and long acting beta agonists. Patients that have asthma may suffer with sudden broncho constriction, generally known as asthmatic attack. Asthmatic attack can be treated with bronchodilators. In emergency conditions, broncho dilators are delivered with specially designed pump for quick relief.

The increase in prevalence of asthma globally drives the growth of asthma and COPD drugs market. For instance, according to report of Global Asthma Network published on 2020, asthma kills around 1000 people every day and affects as many as 339 million people globally. In addition, increase in awareness about the respiratory diseases in people propels the growth of asthma and COPD drugs market. The R&D in the treatment of the asthma by manufacturers and researchers also contributes in the growth of market. Furthermore, initiatives taken by respective governments to treat and improve the lifestyle of asthma & COPD patients boosts market growth. The rise in number of hospitals and well-developed healthcare infrastructure further contributes in market growth.

In addition, increase in the tobacco smoking habits in people and he rise in air pollution contribute in the growth of the asthma and COPD drugs market. However, the high cost of treatment and lack of awareness in people about asthma & COPD are expected to limit the growth of market.

The asthma and COPD drugs market is segmented on the basis of diseases, medication class, and region. By diseases, the market is divided into asthma and COPD. By medication class, the market is divided into combination drugs, inhaled corticosteroids (ics), short acting beta agonists (saba), long acting beta agonists (laba), leukotriene antagonists (lta), anticholinergics and others. By Region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include Abbott Laboratories, AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC., Hoffmann-La Roche Ltd, Novartis AG, Organon, Sanofi, Teva Pharmaceutical Industries Ltd., and Vectura Group plc.

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides an in-depth analysis of the global asthma and COPD drugs market size along with the current trends and future estimations to elucidate the imminent investment pockets
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market
  • A comprehensive analysis of the region assists to understand the regional market and facilitate strategic business planning and determine prevailing opportunities
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global asthma and COPD drugs market growth

KEY MARKET SEGMENTS


By Diseases

  • Asthma
  • COPD

By Medication class

  • Combination drugs
  • Short Acting Beta Agonists (SABA)
  • Long Acting Beta Agonists (LABA)
  • Leukotriene Antagonists (LTA)
  • Anticholinergics
  • Others

By Region

  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • Abbott Laboratories
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline PLC
  • Hoffmann-La Roche Ltd
  • Novartis AG
  • Organon
  • Sanofi
  • Teva Pharmaceutical Industries Ltd
  • Vectura Group plc

Table of Contents

Chapter 1: Introduction
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
Chapter 2: Executive Summary
2.1. Cxo Perspective
Chapter 3: Market Landscape
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power Among Buyers
3.4. Market Share Analysis/Top Player Positioning
3.4.1. Market Share Analysis/Top Player Positioning 2020
3.5. Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. Covid-19 Impact Analysis
Chapter 4: Asthma and Copd Drugs Market, by Diseases
4.1. Market Overview
4.1.1Market Size and Forecast, by Diseases
4.2. Asthma
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, by Region
4.2.3. Market Share Analysis, by Country
4.3. Copd
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, by Region
4.3.3. Market Share Analysis, by Country
Chapter 5: Asthma and Copd Drugs Market, by Medication Class
5.1. Market Overview
5.1.1Market Size and Forecast, by Medication Class
5.2. Combination Drugs
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, by Region
5.2.3. Market Share Analysis, by Country
5.3. Short Acting Beta Agonists (Saba)
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, by Region
5.3.3. Market Share Analysis, by Country
5.4. Long Acting Beta Agonists (Laba)
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, by Region
5.4.3. Market Share Analysis, by Country
5.5. Leukotriene Antagonists (Lta)
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.5.2. Market Size and Forecast, by Region
5.5.3. Market Share Analysis, by Country
5.6. Anticholinergics
5.6.1. Key Market Trends, Growth Factors and Opportunities
5.6.2. Market Size and Forecast, by Region
5.6.3. Market Share Analysis, by Country
5.7. Others
5.7.1. Key Market Trends, Growth Factors and Opportunities
5.7.2. Market Size and Forecast, by Region
5.7.3. Market Share Analysis, by Country
Chapter 6: Asthma and Copd Drugs Market, by Region
6.1. Market Overview
6.1.1Market Size and Forecast, by Region
6.2. Lamea
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, by Diseases
6.2.3. Market Size and Forecast, by Medication Class
6.2.4. Market Size and Forecast, by Country
6.2.5. Brazilasthma and Copd Drugs Market
6.2.5.1. Market Size and Forecast, by Diseases
6.2.5.2. Market Size and Forecast, by Medication Class
6.2.6. South Africa,Asthma and Copd Drugs Market
6.2.6.1. Market Size and Forecast, by Diseases
6.2.6.2. Market Size and Forecast, by Medication Class
6.2.7. Saudi Arabiaasthma and Copd Drugs Market
6.2.7.1. Market Size and Forecast, by Diseases
6.2.7.2. Market Size and Forecast, by Medication Class
6.2.8. Rest of Lameaasthma and Copd Drugs Market
6.2.8.1. Market Size and Forecast, by Diseases
6.2.8.2. Market Size and Forecast, by Medication Class
6.3. North America
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, by Diseases
6.3.3. Market Size and Forecast, by Medication Class
6.3.4. Market Size and Forecast, by Country
6.3.5. United Statesasthma and Copd Drugs Market
6.3.5.1. Market Size and Forecast, by Diseases
6.3.5.2. Market Size and Forecast, by Medication Class
6.3.6. Canadaasthma and Copd Drugs Market
6.3.6.1. Market Size and Forecast, by Diseases
6.3.6.2. Market Size and Forecast, by Medication Class
6.3.7. Mexicoasthma and Copd Drugs Market
6.3.7.1. Market Size and Forecast, by Diseases
6.3.7.2. Market Size and Forecast, by Medication Class
6.4. Europe
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, by Diseases
6.4.3. Market Size and Forecast, by Medication Class
6.4.4. Market Size and Forecast, by Country
6.4.5. Franceasthma and Copd Drugs Market
6.4.5.1. Market Size and Forecast, by Diseases
6.4.5.2. Market Size and Forecast, by Medication Class
6.4.6. Germanyasthma and Copd Drugs Market
6.4.6.1. Market Size and Forecast, by Diseases
6.4.6.2. Market Size and Forecast, by Medication Class
6.4.7. Italyasthma and Copd Drugs Market
6.4.7.1. Market Size and Forecast, by Diseases
6.4.7.2. Market Size and Forecast, by Medication Class
6.4.8. Spainasthma and Copd Drugs Market
6.4.8.1. Market Size and Forecast, by Diseases
6.4.8.2. Market Size and Forecast, by Medication Class
6.4.9. U. Kasthma and Copd Drugs Market
6.4.9.1. Market Size and Forecast, by Diseases
6.4.9.2. Market Size and Forecast, by Medication Class
6.4.10. Rest of Europeasthma and Copd Drugs Market
6.4.10.1. Market Size and Forecast, by Diseases
6.4.10.2. Market Size and Forecast, by Medication Class
6.5. Asia-Pacific
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, by Diseases
6.5.3. Market Size and Forecast, by Medication Class
6.5.4. Market Size and Forecast, by Country
6.5.5. Chinaasthma and Copd Drugs Market
6.5.5.1. Market Size and Forecast, by Diseases
6.5.5.2. Market Size and Forecast, by Medication Class
6.5.6. Japan Asthma and Copd Drugs Market
6.5.6.1. Market Size and Forecast, by Diseases
6.5.6.2. Market Size and Forecast, by Medication Class
6.5.7. India Asthma and Copd Drugs Market
6.5.7.1. Market Size and Forecast, by Diseases
6.5.7.2. Market Size and Forecast, by Medication Class
6.5.8. South Koreaasthma and Copd Drugs Market
6.5.8.1. Market Size and Forecast, by Diseases
6.5.8.2. Market Size and Forecast, by Medication Class
6.5.9. Australia Asthma and Copd Drugs Market
6.5.9.1. Market Size and Forecast, by Diseases
6.5.9.2. Market Size and Forecast, by Medication Class
6.5.10. Rest of Asia-Pacific Asthma and Copd Drugs Market
6.5.10.1. Market Size and Forecast, by Diseases
6.5.10.2. Market Size and Forecast, by Medication Class
Chapter 7: Company Profiles
7.1. Abbott Laboratories
7.1.1. Company Overview
7.1.2. Key Executives
7.1.3. Company Snapshot
7.1.4. Operating Business Segments
7.1.5. Product Portfolio
7.1.6. Business Performance
7.1.7. Key Strategic Moves and Developments
7.2. Astrazeneca plc
7.2.1. Company Overview
7.2.2. Key Executives
7.2.3. Company Snapshot
7.2.4. Operating Business Segments
7.2.5. Product Portfolio
7.2.6. Business Performance
7.2.7. Key Strategic Moves and Developments
7.3. Boehringer Ingelheim International GmbH
7.3.1. Company Overview
7.3.2. Key Executives
7.3.3. Company Snapshot
7.3.4. Operating Business Segments
7.3.5. Product Portfolio
7.3.6. Business Performance
7.3.7. Key Strategic Moves and Developments
7.4. GlaxoSmithKline plc
7.4.1. Company Overview
7.4.2. Key Executives
7.4.3. Company Snapshot
7.4.4. Operating Business Segments
7.4.5. Product Portfolio
7.4.6. Business Performance
7.4.7. Key Strategic Moves and Developments
7.5. Hoffmann-La Roche Ltd
7.5.1. Company Overview
7.5.2. Key Executives
7.5.3. Company Snapshot
7.5.4. Operating Business Segments
7.5.5. Product Portfolio
7.5.6. Business Performance
7.5.7. Key Strategic Moves and Developments
7.6. Novartis AG
7.6.1. Company Overview
7.6.2. Key Executives
7.6.3. Company Snapshot
7.6.4. Operating Business Segments
7.6.5. Product Portfolio
7.6.6. Business Performance
7.6.7. Key Strategic Moves and Developments
7.7. Organon
7.7.1. Company Overview
7.7.2. Key Executives
7.7.3. Company Snapshot
7.7.4. Operating Business Segments
7.7.5. Product Portfolio
7.7.6. Business Performance
7.7.7. Key Strategic Moves and Developments
7.8. Sanofi
7.8.1. Company Overview
7.8.2. Key Executives
7.8.3. Company Snapshot
7.8.4. Operating Business Segments
7.8.5. Product Portfolio
7.8.6. Business Performance
7.8.7. Key Strategic Moves and Developments
7.9. Teva Pharmaceutical Industries Ltd
7.9.1. Company Overview
7.9.2. Key Executives
7.9.3. Company Snapshot
7.9.4. Operating Business Segments
7.9.5. Product Portfolio
7.9.6. Business Performance
7.9.7. Key Strategic Moves and Developments
7.10. Vectura Group plc
7.10.1. Company Overview
7.10.2. Key Executives
7.10.3. Company Snapshot
7.10.4. Operating Business Segments
7.10.5. Product Portfolio
7.10.6. Business Performance
7.10.7. Key Strategic Moves and Developments
List of Tables
Table 1. Global Asthma and Copd Drugs Market, by Diseases, 2020-2030 ($Million)
Table 2. Global Asthma and Copd Drugs Market for Asthma, by Region, 2020-2030 ($Million)
Table 3. Global Asthma and Copd Drugs Market for Copd, by Region, 2020-2030 ($Million)
Table 4. Global Asthma and Copd Drugs Market, by Medication Class, 2020-2030 ($Million)
Table 5. Global Asthma and Copd Drugs Market for Combination Drugs, by Region, 2020-2030 ($Million)
Table 6. Global Asthma and Copd Drugs Market for Short Acting Beta Agonists (Saba), by Region, 2020-2030 ($Million)
Table 7. Global Asthma and Copd Drugs Market for Long Acting Beta Agonists (Laba), by Region, 2020-2030 ($Million)
Table 8. Global Asthma and Copd Drugs Market for Leukotriene Antagonists (Lta), by Region, 2020-2030 ($Million)
Table 9. Global Asthma and Copd Drugs Market for Anticholinergics, by Region, 2020-2030 ($Million)
Table 10. Global Asthma and Copd Drugs Market for Others, by Region, 2020-2030 ($Million)
Table 11. Global Asthma and Copd Drugs Market, by Region, 2020-2030 ($Million)
Table 12. Lamea Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 13. Lamea Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 14. Brazil Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 15. Brazil Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 16. South Africa, Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 17. South Africa, Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 18. Saudi Arabia Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 19. Saudi Arabia Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 20. Rest of LAMEA Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 21. Rest of LAMEA Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 22. North America Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 23. North America Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 24. United States Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 25. United States Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 26. Canada Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 27. Canada Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 28. Mexico Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 29. Mexico Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 30. Europe Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 31. Europe Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 32. France Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 33. France Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 34. Germany Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 35. Germany Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 36. Italy Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 37. Italy Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 38. Spain Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 39. Spain Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 40. United Kingdom Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 41. United Kingdom Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 42. Rest of Europe Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 43. Rest of Europe Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 44. Asia-Pacific Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 45. Asia-Pacific Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 46. China Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 47. China Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 48. Japan Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 49. Japan Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 50. India Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 51. India Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 52. South Korea Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 53. South Korea Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 54. Australia Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 55. Australia Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 56. Rest of Asia-Pacific Asthma and Copd Drugs, by Diseases, 2020-2030 ($Million)
Table 57. Rest of Asia-Pacific Asthma and Copd Drugs, by Medication Class, 2020-2030 ($Million)
Table 58. Abbott Laboratories: Key Executives
Table 59. Abbott Laboratories: Company Snapshot
Table 60. Abbott Laboratories: Operating Segments
Table 61. Abbott Laboratories: Product Portfolio
Table 62. Abbott Laboratories: Key Strategic Moves and Developments
Table 63. Astrazeneca plc: Key Executives
Table 64. Astrazeneca plc: Company Snapshot
Table 65. Astrazeneca plc: Operating Segments
Table 66. Astrazeneca plc: Product Portfolio
Table 67. Astrazeneca plc: Key Strategic Moves and Developments
Table 68. Boehringer Ingelheim International Gmbh: Key Executives
Table 69. Boehringer Ingelheim International Gmbh: Company Snapshot
Table 70. Boehringer Ingelheim International Gmbh: Operating Segments
Table 71. Boehringer Ingelheim International Gmbh: Product Portfolio
Table 72. Boehringer Ingelheim International Gmbh: Key Strategic Moves and Developments
Table 73. GlaxoSmithKline plc: Key Executives
Table 74. GlaxoSmithKline plc: Company Snapshot
Table 75. GlaxoSmithKline plc: Operating Segments
Table 76. GlaxoSmithKline plc: Product Portfolio
Table 77. GlaxoSmithKline plc: Key Strategic Moves and Developments
Table 78. Hoffmann-La Roche Ltd: Key Executives
Table 79. Hoffmann-La Roche Ltd: Company Snapshot
Table 80. Hoffmann-La Roche Ltd: Operating Segments
Table 81. Hoffmann-La Roche Ltd: Product Portfolio
Table 82. Hoffmann-La Roche Ltd: Key Strategic Moves and Developments
Table 83. Novartis Ag: Key Executives
Table 84. Novartis Ag: Company Snapshot
Table 85. Novartis Ag: Operating Segments
Table 86. Novartis Ag: Product Portfolio
Table 87. Novartis Ag: Key Strategic Moves and Developments
Table 88. Organon: Key Executives
Table 89. Organon: Company Snapshot
Table 90. Organon: Operating Segments
Table 91. Organon: Product Portfolio
Table 92. Organon: Key Strategic Moves and Developments
Table 93. Sanofi: Key Executives
Table 94. Sanofi: Company Snapshot
Table 95. Sanofi: Operating Segments
Table 96. Sanofi: Product Portfolio
Table 97. Sanofi: Key Strategic Moves and Developments
Table 98. Teva Pharmaceutical Industries Ltd: Key Executives
Table 99. Teva Pharmaceutical Industries Ltd: Company Snapshot
Table 100. Teva Pharmaceutical Industries Ltd: Operating Segments
Table 101. Teva Pharmaceutical Industries Ltd: Product Portfolio
Table 102. Teva Pharmaceutical Industries Ltd: Key Strategic Moves and Developments
Table 103. Vectura Group plc: Key Executives
Table 104. Vectura Group plc: Company Snapshot
Table 105. Vectura Group plc: Operating Segments
Table 106. Vectura Group plc: Product Portfolio
Table 107. Vectura Group plc: Key Strategic Moves and Developments
List of Figures
Figure 1. Global Asthma and Copd Drugs Market Segmentation
Figure 2. Global Asthma and Copd Drugs Market
Figure 3. Segmentation Asthma and Copd Drugs Market
Figure 4. Top Investment Pocket in Asthma and Copd Drugs Market
Figure 5. Top Winning Strategies, 2019-2021*
Figure 6. Top Winning Strategies, by Development, 2019-2021(%)
Figure 7. Top Winning Strategies, by Company, 2019-2021*
Figure 8. Moderate Bargaining Power of Buyers
Figure 9. Moderate Bargaining Power of Suppliers
Figure 10. Moderate Threat of New Entrants
Figure 11. Low Threat of Substitution
Figure 12. High Competitive Rivalry
Figure 13. Top Player Positioning, 2020
Figure 14. Market Share Analysis, 2020
Figure 15. Restraints and Drivers: Asthma and Copd Drugs Market
Figure 16. Asthma and Copd Drugs Market Segmentation, by Diseases
Figure 17. Asthma and Copd Drugs Market for Asthma, by Country, 2020-2030 ($ Million)
Figure 18. Asthma and Copd Drugs Market for Copd, by Country, 2020-2030 ($ Million)
Figure 19. Asthma and Copd Drugs Market Segmentation, by Medication Class
Figure 20. Asthma and Copd Drugs Market for Combination Drugs, by Country, 2020-2030 ($ Million)
Figure 21. Asthma and Copd Drugs Market for Short Acting Beta Agonists (Saba), by Country, 2020-2030 ($ Million)
Figure 22. Asthma and Copd Drugs Market for Long Acting Beta Agonists (Laba), by Country, 2020-2030 ($ Million)
Figure 23. Asthma and Copd Drugs Market for Leukotriene Antagonists (Lta), by Country, 2020-2030 ($ Million)
Figure 24. Asthma and Copd Drugs Market for Anticholinergics, by Country, 2020-2030 ($ Million)
Figure 25. Asthma and Copd Drugs Market for Others, by Country, 2020-2030 ($ Million)
Figure 26. Abbott Laboratories: Net Sales, 2018-2020 ($ Million)
Figure 27. Abbott Laboratories: Revenue Share, by Segment, 2020 (%)
Figure 28. Abbott Laboratories: Revenue Share, by Region, 2020 (%)
Figure 29. Astrazeneca plc: Net Sales, 2018-2020 ($ Million)
Figure 30. Astrazeneca plc: Revenue Share, by Segment, 2020 (%)
Figure 31. Astrazeneca plc: Revenue Share, by Region, 2020 (%)
Figure 32. Boehringer Ingelheim International Gmbh: Net Sales, 2018-2020 ($ Million)
Figure 33. Boehringer Ingelheim International Gmbh: Revenue Share, by Segment, 2020 (%)
Figure 34. Boehringer Ingelheim International Gmbh: Revenue Share, by Region, 2020 (%)
Figure 35. GlaxoSmithKline plc: Net Sales, 2018-2020 ($ Million)
Figure 36. GlaxoSmithKline plc: Revenue Share, by Segment, 2020 (%)
Figure 37. GlaxoSmithKline plc: Revenue Share, by Region, 2020 (%)
Figure 38. Hoffmann-La Roche Ltd: Net Sales, 2018-2020 ($ Million)
Figure 39. Hoffmann-La Roche Ltd: Revenue Share, by Segment, 2020 (%)
Figure 40. Hoffmann-La Roche Ltd: Revenue Share, by Region, 2020 (%)
Figure 41. Novartis Ag: Net Sales, 2018-2020 ($ Million)
Figure 42. Novartis Ag: Revenue Share, by Segment, 2020 (%)
Figure 43. Novartis Ag: Revenue Share, by Region, 2020 (%)
Figure 44. Organon: Net Sales, 2018-2020 ($ Million)
Figure 45. Organon: Revenue Share, by Segment, 2020 (%)
Figure 46. Organon: Revenue Share, by Region, 2020 (%)
Figure 47. Sanofi: Net Sales, 2018-2020 ($ Million)
Figure 48. Sanofi: Revenue Share, by Segment, 2020 (%)
Figure 49. Sanofi: Revenue Share, by Region, 2020 (%)
Figure 50. Teva Pharmaceutical Industries Ltd: Net Sales, 2018-2020 ($ Million)
Figure 51. Teva Pharmaceutical Industries Ltd: Revenue Share, by Segment, 2020 (%)
Figure 52. Teva Pharmaceutical Industries Ltd: Revenue Share, by Region, 2020 (%)
Figure 53. Vectura Group plc: Net Sales, 2018-2020 ($ Million)
Figure 54. Vectura Group plc: Revenue Share, by Segment, 2020 (%)
Figure 55. Vectura Group plc: Revenue Share, by Region, 2020 (%)

Executive Summary

According to a new report titled, “Asthma and COPD drugs market by Disease and Medication Class: Global Opportunity Analysis and Industry Forecast, 2021–2030, the asthma and COPD drugs market size was valued at $32988.7 million in 2020 and is projected to reach $52049.54 million by 2030, registering a CAGR of 4.64% from 2021 to 2030.

Asthma is respiratory condition marked by attacks of spasm in the bronchi of lungs, causing difficulty in breathing. It is usually connected to allergic reactions or other forms of hypersensitivity. COPD is a group of respiratory diseases, in which there is constriction of airways and difficulty or discomfort in breathing.

The asthma and COPD can be prevented and treated with drugs such as corticosteroids, short-acting beta agonists, and anticholinergic drugs. In the acute asthmatic attack, patient feels difficulty to breathe due to sudden narrowing of bronchi, generally due to allergens. In acute asthmatic attack, bronchodilators give quick relief and can be life saving for patients.

Factors that drive the growth of the asthma and COPD drugs market include the rise in number of hospitals, increase in number of asthma patients, and advancement in respiratory diseases treatment. For instance, according to World Health Organization (WHO), COPD was the third leading cause of death globally, causing 3.23 million deaths in 2019. Furthermore, government initiatives for the management of respiratory diseases contribute in the growth of the asthma and COPD drugs market.

The asthma and COPD drugs market is segmented on the basis of diseases, medication class, and region.

By diseases, the market is divided into asthma and COPD. The asthma segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to the increase in number patients suffering from asthma.

By medication class, the market is divided into combination drugs, inhaled corticosteroids (ics), short acting beta agonists (saba), long acting beta agonists (laba), leukotriene antagonists (lta), anticholinergics, and others. The combination drugs segment dominated the market in 2020, and this trend is expected to continue during the forecast period, due to high prevalence of respiratory diseases and tobacco smoking habit.

North America accounted for a majority of the global asthma and COPD drugs market share in 2020, and is anticipated to remain dominant during the forecast period. Asia-Pacific is anticipated to witness lucrative growth, owing to the increase in number of asthma and COPD patients.

The COVID-19 outbreak is anticipated to have a negative impact on the growth of the asthma and COPD drugs market as most hospitals are not operating due to COVID-19 and the ongoing lockdowns in many countries. The COVID-19 virus has serious and life-threatening impact on patients with respiratory disorders. However, a huge number of clinics and hospitals across the globe were restructured to increase the hospital capacity for the patient diagnosed with COVID-19, and this is expected to increase the diagnosis and treatment of respiratory diseases, which contributes in the market growth.

Key Findings Of Study


  • On the basis of diseases, the asthma segment was the highest contributor to the market in 2020
  • On the basis of medication class, combination drug segment dominated the market in 2020
  • On the basis of region, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period

Companies Mentioned

  • Abbott Laboratories
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline PLC.
  • Hoffmann-La Roche Ltd.
  • Novartis AG
  • Organon
  • Sanofi
  • Teva Pharmaceutical Industries Ltd
  • Vectura Group plc.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedFebruary 2022
Forecast Period2020 - 2030
Estimated Market Value ( USD ) in 2020 $ 32988.7 million
Forecasted Market Value ( USD ) by 2030 $ 52049.54 million
Compound Annual Growth Rate4.7%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Asthma and COPD Drugs Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Asthma and COPD Drugs Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Anti-Asthmatics and COPD Drugs Global Market Report 2024 - Product Image

Anti-Asthmatics and COPD Drugs Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2024 - Product Image

Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Global Pulmonary Drugs Market by Drug Class (Anti-Cholinergic Agents, Anti-Leukotrienes, Antihistamines), Indication (Allergic Rhinitis, Asthma, Chronic Obstructive Pulmonary Disease), Drug Type, Distribution Channel, End-User - Forecast 2023-2030 - Product Image

Global Pulmonary Drugs Market by Drug Class (Anti-Cholinergic Agents, Anti-Leukotrienes, Antihistamines), Indication (Allergic Rhinitis, Asthma, Chronic Obstructive Pulmonary Disease), Drug Type, Distribution Channel, End-User - Forecast 2023-2030

  • Report
  • 184 Pages
  • Global
From
Asthma & COPD Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Asthma & COPD Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 79 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.